Search

The selective estrogen receptor modulator (SERM) and an agent for the prevention of osteoporosis in postmenopausal women, raloxifene (Ral), decreased high-dose methotrexate (MTX) cytotoxicity in MCF-7 breast cancer cells. When Ral is given at least 24 hours prior to MTX, the resultant interaction is antagonistic. However, when breast cancer cells are exposed to Ral 24 hours after MTX, the interaction between Ral and MTX is not antagonistic. The proliferation of cells exposed to 10 microM Ral and 10 microM MTX alone or in combination with Ral 24 hours prior to MTX was in had the following order: MTXRal 24 hours prior to MTXRal. MTX administration 24 hours prior to Ral had the following inhibitory effects on the growth of cells: MTX 24 hours prior to Ralor = MTXRal 24 hours prior to MTXRalcontrol (no drug exposure). To determine if the antagonistic interaction between Ral and MTX was a function of sequence and time, cells were exposed to Ral 24 hours and 36 hours prior to MTX exposure. The percentages of control rates were 43.48 +/- 3.90% and 54.43 +/- 2.93%, respectively, from a 24 hours and 36 hours exposure of Ral prior to MTX. The growth rates after 24 h and 36 h exposures to MTX alone were 30.30 +/- 0.61% and 33.11 +/- 2.27% of control rates, respectively. These studies suggest that: (a) the interactions between Ral and MTX are sequence-dependent; (b) Ral antagonizes the effect of MTX when Ral administration precedes MTX; and (c) Ral antagonism to MTX is a function of time.

— Monoamine oxidase (MAO) activity against tryptamine was compared in a number of continuous rodent lines, including neuroblastoma, hepatoma, melanoma, nephroma, sarcoma and L cells. Activities against tryptamine varied over 300-fold in homogenates of different lines, being highest in hepatoma line MH1C1 and lowest in a neuroblastoma line lacking hypoxanthine phosphoribosyltransferase (HPRT) activity. The amount, but not the type, of MAO activity varied with the stage of growth in homogenates of neuroblastoma and hepatoma cells. Measurements of succinate-cytochrome c reductase (SCCR), another mitochondrial enzyme, also showed 20-fold variations between lines, being highest in neuroblastoma line N1E-115 and lowest in hepatoma line MH1C1; SCCR and MAO activities appeared to be regulated independently. The relative proportions of the A and B types of MAO activity were determined in homogenates and living cultures. Clorgyline inhibition of tryptamine deamination in homogenates indicated that in all lines except MH1C1, greater than 95% of the MAO activity was of the A type. In MH1C1 homogenates, using clorgyline or deprenyl, 40–70% of the activity appeared to be of the A type and 30-60% of the B type. In cultures of neuroblastoma N1E-115 cells, deamination of tryptamine and dopamine was sensitive to inhibition by low concentrations of clorgyline, indicating that the A type of activity is present intracellularly. as in homogenates. In MH1C1 hepatoma cultures, tryptamine deamination showed a biphasic sensitivity to clorgyline. We interpret this to mean that A and B types of MAO activity occur together in living hepatoma cells.

The inheritance of monoamine oxidase (MAO; EC1.4.3.4) was studied in cultured cells using techniques of somatic cell genetics. Cells of a mouse neuroblastoma variant line lacking MAO activity were fused to cytoplasts prepared from a mouse L cell line which expresses MAO activity and is resistant to chloramphenicol (a cytoplasmically inherited trait). The resulting cybrids were resistant to chloramphenicol, but did not recover MAO activity, indicating that the loss of activity in the neuroblastoma parent was not the result of an inherited lesion in a cytoplasmically transmitted gene. This cybrid cells were then fused to rat hepatoma cells expressing both A and B types of MAO activity. A resulting hybrid line, grown in medium containing hypoxanthine, aminopterin and thymidine (HAT) to select cells that had retained HPRT activity and hence the rat X chromosome, expressed both types of activity, but at a reduced level compared to the hepatoma parent. This finding indicates that the genetic lesion in the neuroblastoma cells resulting in loss of MAO activity is not phenotypically dominant, and that both A and B types of activity can be conferred together to neuroblastoma cells which normally express only the A type of MAO activity.

Monoamine oxidase (MAO) (monoamine: O2 oxidoreductase EC 1.4.3.4.) is located in the mitochondrial outer membrane and is the enzyme primarily responsible for the degradation of catecholamines and other biogenic amines in the nervous system (Houslay et al., 1976; Murphy, 1978). The enzyme is believed to be comprised of two subunits of approximate molecular weight 60,000, with one subunit containing a covalently bound flavin co-factor (Minamiura and Yasunobu, 1978; Salach, 1979). Two types of MAO activity, A and B, have been defined by characteristic substrate preferences and inhibitor sensitivities (Johnston, 1968; Garrick and Murphy, 1980).